Anti-cancer immunotherapy drug with reduced side effects and increased therapeutic effects
Development of anti-cancer drugs that boost patient immunity. Potential for immunotherapy drug with no side effects
2021-06-28
(Press-News.org) Unlike conventional cancer drugs that attack and kill cancer cells directly, anti-cancer immunotherapy, which kills cancer cells by strengthening the body's immunity, is a novel type of cancer treatment currently attracting increased attention. Unfortunately, a minority of cancer patients who have some degree of pre-existing immunity only benefit from anti-cancer immunotherapy.
Recently, 'doxorubicin', a cancer treatment drug, has been shown to boost patients' immune response by releasing various components when cancer cells are killed. However, as the toxicity and inflammatory responses induced by doxorubicin can affect normal cells in addition to cancer cells, it can lower patients' immunity levels, which limits its effectiveness for immunotherapy.
To tackle this issue, a research team led by Dr. Ju Hee Ryu of the Center for Theragnosis at the Korea Institute of Science and Technology (KIST) has developed an anti-cancer prodrug that can improve anti-cancer immunotherapy by reacting only with cancer cells, thereby minimizing the toxicity to normal cells, including immune cells, and boosting patient immunity.
Last year, the Center for Theragnosis at KIST reported the development of an anti-cancer drug that targets cancer cells by suppressing the resistance to doxorubicin without reacting with normal cells. In contrast, Dr. Ryu's research team has developed a prodrug for anti-cancer immunotherapy that utilizes the immunity-boosting potential of doxorubicin.
The developed prodrug exhibits anticancer effects when activated by abundant enzymes present in cancer cells. As these enzymes are not present in normal cells, they do not experience toxicity and inflammatory responses. The ability to target cancer cells exclusively increases patient immunity, inducing an active anticancer immune response when doxorubicin is activated in cancer cells.
The developed anti-cancer drug significantly improved the anti-cancer immune response in nonclinical animal models and reduced side effects associated with inflammatory responses and toxicity in normal tissues. Therefore, the drug dosage can probably be increased to enhance its effectiveness for chemotherapy without causing notable side effects.
In addition, because the prodrug was developed by utilizing a drug already in clinical use, the commercialization process is expected to be relatively straightforward in terms of clinical trials and mass production.
Dr. Ju Hee Ryu of KIST said, "Because the immunity level of most patients must be raised to a certain level to enjoy the remarkable therapeutic effect of immunotherapy, an anti-cancer prodrug that can maintain the anti-cancer immune response of the drug while reducing the toxicity and inflammatory responses in normal tissues represents a significant step forward for immunotherapy."
INFORMATION:
This study was conducted as a mid-career researcher program of the National Research Foundation of Korea with the support of the Ministry of Science and ICT (MSIT). The research results are published in the latest issue of 'Biomaterials' (IF:10.317, top 2.6% in the field of JCR), a leading international journal in the field of materials and biomaterials.
[Attachments] See images for this press release:
ELSE PRESS RELEASES FROM THIS DATE:
2021-06-28
Oncotarget published "Glucocorticoid receptor antagonism promotes apoptosis in solid tumor cells" which reported that to guide studies in cancer patients, relacorilant, an investigational selective GR modulator that antagonizes cortisol activity, was assessed in various tumor types, with multiple cytotoxic combination partners, and in the presence of physiological cortisol concentrations.
In the MIA PaCa-2 cell line, paclitaxel-driven apoptosis was blunted by cortisol and restored by relacorilant.
A screen to identify optimal combination partners for relacorilant showed that microtubule-targeted agents consistently ...
2021-06-28
PHILADELPHIA-- In addition to sickening and taking the lives of millions across the globe, COVID-19 complicated patient care in a range of less-direct ways, from increased incidence of END ...
2021-06-28
HAMILTON, ON June 28, 2021 -- Researchers at McMaster University have developed a promising new cancer immunotherapy that uses cancer-killing cells genetically engineered outside the body to find and destroy malignant tumors.
The modified "natural killer" cells can differentiate between cancer cells and healthy cells that are often intermingled in and around tumors, destroying only the targeted cells.
The natural killer cells' ability to distinguish the target cells, even from healthy cells that bear similar markers, brings new promise to this branch of immunotherapy, say ...
2021-06-27
A few males are enough to fertilise all the females. The number of males therefore has little bearing on a population's growth. However, they are important for purging bad mutations from the population. This is shown by a new Uppsala University study providing in-depth knowledge of the possible long-term genetic consequences of sexual selection. The results are published in the scientific journal Evolution Letters.
The study supports the theory that in many animal species selection acting on males can impose the fortuitous benefit to the population of causing offspring to inherit healthy genes. Stiff competition among males results ...
2021-06-26
Tokyo, Japan - Researchers from Tokyo Metropolitan University have discovered that a specific chemical feature of a key protein known as tau may cause it to accumulate in the brain and trigger illnesses like Alzheimer's. They found that disulfide bonds on certain amino acids act to stabilize tau and cause it to accumulate, an effect that got worse with increased oxidative stress. The identification of chemical targets triggering tau accumulation may lead to breakthrough treatments.
The tau protein is key to the healthy function of biological cells. It helps form and stabilize microtubules, the thin filaments that crisscross cell interiors to help keep them structurally rigid and provide 'highways' to shuttle molecules between organelles. However, when they ...
2021-06-26
A new vaccine to protect against deadly cholera has been made by grinding up genetically modified grains of rice. The first human trial has shown no obvious side effects and a good immune response. Researchers based at the University of Tokyo and Chiba University have published the peer-reviewed results of the Phase 1 clinical trial of the vaccine, named MucoRice-CTB, in The Lancet Microbe.
Vaccine manufacturing has made enormous strides in 2020, spurred on by COVID-19. However, the complexity of mRNA-based SARS-CoV-2 vaccines has highlighted the value of inoculations that can be made, transported and stored cheaply and without refrigeration.
The MucoRice-CTB vaccine is stable at room temperature from start to finish.
"I'm very optimistic for the future of our MucoRice-CTB vaccine, ...
2021-06-26
Just as humans have their own individual personalities, new research in the Journal of Comparative Psychology shows that elephants have personalities, too. Moreover, an elephant's personality may play an important role in how well that elephant can solve novel problems.
The article was written by Lisa Barrett and Sarah Benson-Amram in the University of Wyoming's Animal Behavior and Cognition Lab, led by Benson-Amram. It may be viewed here.
The authors of the paper tested 15 Asian elephants and three African savanna elephants in three zoos across the country -- the San Diego Zoo, the Smithsonian's National Zoological Park and the Oklahoma City Zoo -- with the help of elephant caretakers.
Previous work from Barrett and Benson-Amram demonstrated ...
2021-06-26
FINDINGS
A UCLA-led study comparing brain cells known as astrocytes in humans and mice found that mouse astrocytes are more resilient to oxidative stress, a damaging imbalance that is a mechanism behind many neurological disorders. A lack of oxygen triggers molecular repair mechanisms in these mouse astrocytes but not in human astrocytes. In contrast, inflammation activates immune-response genes in human astrocytes but not mouse astrocytes.
BACKGROUND
Although the mouse is a ubiquitous laboratory model used in research for neurological diseases, results from studies in mice are not always applicable to humans. In fact, more than 90% of drug candidates that show preclinical promise for neurological disorders ultimately fail when tested in humans, in part ...
2021-06-25
Crude oil production and natural gas withdrawals in the United States have lessened the country's dependence on foreign oil and provided financial relief to U.S. consumers, but have also raised longstanding concerns about environmental damage, such as groundwater contamination.
A researcher in Syracuse University's College of Arts and Sciences, and a team of scientists from Penn State, have developed a new machine learning technique to holistically assess water quality data in order to detect groundwater samples likely impacted by recent methane leakage during oil and gas production. Using that model, the team concluded that unconventional drilling ...
2021-06-25
Irvine, CA - June 25, 2021 - New research from the University of California, Irvine reveals how the circadian regulation of glucose production in the liver is lost during lung cancer progression, and how the resulting increase in glucose production may fuel cancer cell growth.
The new study titled, "Glucagon regulates the stability of REV-ERBα to modulate hepatic glucose production in a model of lung cancer-associated cachexia," published today in Science Advances, illustrates how the circadian clock is regulated under conditions of stress such as during lung cancer progression and cancer-associated tissue wasting ...
LAST 30 PRESS RELEASES:
[Press-News.org] Anti-cancer immunotherapy drug with reduced side effects and increased therapeutic effects
Development of anti-cancer drugs that boost patient immunity. Potential for immunotherapy drug with no side effects
